CytomX Therapeutics
CTMX
88 hedge funds and large institutions have $97.1M invested in CytomX Therapeutics in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 19 increasing their positions, 24 reducing their positions, and 8 closing their positions.
3,430% more call options, than puts
Call options by funds: $353K | Put options by funds: $10K
250% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 8
92% more capital invested
Capital invested by funds: $50.6M → $97.1M (+$46.5M)
29% more funds holding
Funds holding: 68 → 88 (+20)
17.06% more ownership
Funds ownership: 48.73% → 65.79% (+17%)
21% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$6.54M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.69M |
| 3 |
SCM
Sio Capital Management
New York
|
+$2.95M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.35M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$706K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$609K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$574K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$483K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$400K |
CTMX Hedge Fund Activity: Q1 2024 in Review
88 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2024, worth a combined $97.1M — up 92% from $50.6M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CTMX positions and 8 closed out — a net gain of 20 holders — while 19 added to existing stakes and 24 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $6.54M. The largest seller was Fidelity Investments, cutting an estimated $706K.
- 88 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2024, up from 68 in Q4 2023.
- Funds reported $97.1M of CytomX Therapeutics stock for Q1 2024, up 92% quarter-over-quarter.
- 28 funds opened new CytomX Therapeutics positions in Q1 2024 and 8 closed out, a net change of +20 holders.
- The largest CytomX Therapeutics buyer in Q1 2024 was OrbiMed, an estimated $6.54M added.
- The largest CytomX Therapeutics seller in Q1 2024 was Fidelity Investments, an estimated $706K sold.
Based on aggregated 13F filings for Q1 2024.